We have shown through re-expression of PDE4D7 in the knockdown LNCaP cells via either transient DNA transfection or an inducible Tet-On system that we can not only restore a reduced growth phenotype but also re-sensitise cells to treatments such as enzalutamide and olaparib, highlighting the potential for manipulating PDE4D7 gene expression as a novel therapeutic avenue for PCa, independent of AR-targeting treatments. This evidence concerns the gene AR and posterior cortical atrophy.